Latest News and Press Releases

Pharmala announces a newly signed contract to supply a clinical trial, and the fulfillment of a previously announced trial.

PharmAla to receive clinical trial data from harvard-affiliated hospital in exchange for a drug donation

PharmAla to supply University of Amsterdam with LaNeo MDMA for a clinical trial, generating new stability data for blister packs in the process

PharmAla announces the resignation of Dr. Malik Slassi and the appointment of Mr Lennie Ryer to its board.

PharmAla inks contract with Ostfold Hospital Trust in Oslo to supply clinical trial in exchange for both cash and a data license

PharmAla files its audited year end and unaudited Q1 financials.

PharmAla ships MDMA to Mt. Sinai Hospital and starts making patented novel MDMA-like drug, preparing for a phase 2 clinical trial into Social Anxiety.

PharmAla completes delivery of a Phase 3 clinical trial contract after finishing release testing on an australian-made batch of LaNeo MDMA.

PharmAla files its final short form prospectus, and announces a signed term sheet with an R&D tax credit financing firm called Radium

PharmAla launches new web portal for MDMA prescribers and appoints a new COO